Current Issue

VOL 11 NO 5 • JULY 2020

This issue’s cover illustration depicts diffuse large B-cell lymphoma and the novel agent polatuzumab vedotin. Polatuzumab vedotin is an antibody-drug conjugate comprising a cytotoxin bound to a monoclonal antibody that binds to CD79b on the B-cell tumor surface, inhibiting division and inducing apoptosis. Cytotoxin is indicated in red. Artwork by Alexandra Webber Baker © 2020, DNA Illustrations, Inc., Asheville, North Carolina.

Research and Scholarship

Using Social Media as a Platform for Increasing Knowledge of Lung Cancer Screening in High-Risk Patients

Aimee Strong,(1) DNP, RN, AGACNP-BC, and Michelle Renaud,(2) RN, PhD

According to the American Cancer Society (2020), lung cancer is the leading cause of adult cancer-related deaths in the United States, with approximately 228,820 new cases and 135,720 deaths predicted in 2020. The National Lung Screening Trial reported that annual low-dose CT of the chest (LDCT) ...

Research and Scholarship

Nutritional Risk in Cancer Patients 65 and Older Undergoing Systemic Phase I Treatment

Anna Cathy Williams, RN, PhD, PHN, Ed

Phase I trials are rigorous treatments, and geriatric patients are extremely vulnerable to the known and unknown side effects of treatments (McMahon, Decker, & Ottery, 1998). Nutrition plays a major but not always fully understood role in many aspects of cancer development and treatment. Nutr...

Review Article

Nausea and Vomiting Not Related to Cancer Therapy: Intractable Problem or Clinical Challenge?

Rita J. Wickham, PhD, RN

Over the past 40 years, major advances in knowledge and new drugs targeting chemotherapy-induced nausea and vomiting (CINV) have been incorporated into (largely) evidence-based antiemetic guidelines. Conversely, there is a thin evidence base underpinning guidelines for the palliative management o...

Review Article

Phase 1 Clinical Trials in the Elderly: Enrollment Challenges

Carol Guarnieri, RN, MSN, FNP-C, and Daniel D. Von Hoff, MD, FACP, FASCO, FAACR

Cancer is the second most common cause of death in the United States, exceeded only by heart disease, and accounts for nearly one out of four deaths (American Cancer Society, 2018). Age is the greatest risk factor for developing cancer. Approximately 60% of people who have a diagnosis of cancer a...

Grand Rounds

A Patient-Centered Approach for the Treatment of Fungating Breast Wounds

Karlyn L. Rupert, MPAS, PA-C, and Andrea J. Fehl, CRNP, AOCNP®

Case Study LB is a 51-year-old postmenopausal female with no significant past medical history who presented to the emergency department with a fungating breast mass. She delayed seeking medical care, as she was the primary caregiver for her daughter with developmental delays. Staging CT scans of ...

Practice Matters

Patient-Reported Outcomes and Assessment of Quality of Life: A Focus on Multiple Myeloma

MaryAnn Fragola, ANP-C, DNP

Many new treatment regimens have become available for patients with malignancies, particularly for patients with multiple myeloma (MM). As a result, MM has been increasingly described as a chronic illness. Newer modalities of treatment mean that patients must learn how to live with treatments whi...

Prescriber's Corner

Polatuzumab Vedotin for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Transplant-Ineligible Patients

Melanie Douglas, MS, PA-C

Lymphoma is the most common hematologic malignancy, accounting for 5% of newly diagnosed malignancies (Ku, Chong, & Hawkes, 2017; National Cancer Institute, 2019). In the United States, approximately 2.2% of individuals will be diagnosed with non-Hodgkin lymphoma (NHL) in their lifetime (Nati...

Section Seperator
Section Seperator
Section Seperator
Section Seperator
Copyright © 2010-2019 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.